Defining the future of treatment for people with immune-mediated diseases

Jaideep is founding CEO of Ouro Medicines. He was most recently part of the founding team of Human Immunology Biosciences (HI-Bio), where he led portfolio development and strategy prior to the acquisition by Biogen. Jaideep was also the program team leader for felzartamab, an anti-CD38 monoclonal antibody, currently in late-stage development for the treatment of immune-mediated kidney diseases. Previously, he was at Relay Therapeutics, a precision medicine company focused on oncology and rare genetic diseases, where he played a cross-functional role in R&D, strategy and business development. He started his career at Vida Ventures as an associate. Jaideep is also a Portfolio Principal at Monograph Capital and an observer on the board of Sudo Biosciences. He completed his PhD at MIT in Biological Engineering and holds a BS in Bioengineering from UCLA.

Neely Mozaffarian, MD, PhD, is the Chief Medical Officer at Ouro Medicines, with over 20 years of research experience in autoimmune and autoinflammatory diseases. Prior to Ouro, Neely was the Chief Medical Officer at GentiBio and Atomwise, with large pharma experience at Johnson & Johnson, Gilead, Eli Lilly, and AbbVie, leading drug development of biologics and small molecules across clinical trial phases 1-4. Neely’s research interests center on restoration of immune homeostasis in autoimmune and inflammatory diseases. She graduated with honors (Alpha Omega Alpha) from the Medical Scientist Training Program at Albert Einstein College of Medicine in NY, and completed Internal Medicine Residency and Rheumatology Fellowship at the University of Washington in Seattle.

Christina brings nearly 20 years of pharmaceutical and legal experience to her role as Chief Operating Officer at Ouro Medicines. Partnering with teams throughout Ouro, she is responsible for various matters, including human resources, public affairs and all legal matters, such as licensing, collaborations, compliance, corporate governance, and intellectual property. Prior to joining Ouro Christina served as General Counsel of Human Immunology Biosciences (HIBio), and before HIBio, as Vice President, Corporate Legal and Assistant Secretary at Gilead Sciences. During her time at HIBio and Gilead, Christina led legal teams supporting operations in the United States and Latin America and was involved in the structuring and execution of numerous acquisitions, divestitures, and strategic collaborations. She started her career at the law firm Wilson Sonsini Goodrich & Rosati.

Christina received her J.D. from Santa Clara University Law School and a bachelor’s degree in Biotechnology from the University of California, Davis.

Tyler is the Vice President of Corporate Development at Ouro Medicines. Prior to Ouro, he was the Head of Corporate Development and Alliance Management at HI-Bio through the acquisition and integration with Biogen. Tyler has spent his career in partnering and strategy roles in the biopharmaceutical industry including at BeiGene and Spark Therapeutics. He completed his PhD in chemistry at Johns Hopkins University and a bachelor’s in chemistry from Sonoma State University.

Leslie Chinn is the Vice President of Development Sciences at Ouro Medicines. Prior to joining Ouro, Leslie led clinical pharmacology and translational science efforts for molecules such as felzartamab and fenebrutinib at HI-Bio/Biogen, Equillium, Principia Biopharma/Sanofi, and Genentech, primarily in the immunology therapeutic area. She began her career as a clinical pharmacology reviewer at the FDA where she contributed to the review and approval of the first direct-acting agents against hepatitis C virus. Leslie earned a BS in Biochemistry from the University of Michigan and a PhD in Pharmaceutical Sciences & Pharmacogenomics from UCSF and subsequently completed postdoctoral training at the NIH and FDA.

Ruth is the Vice President of Research & Translation at Ouro Medicines, bringing more than 15 years of leadership in immunology, immuno-oncology, and translational sciences. She most recently led translational and research efforts at Asher Biotherapeutics, contributing to multiple clinical and discovery-stage programs. Previously, at Bristol Myers Squibb, she directed the CCR8 program from inception through IND submission, spearheaded patient-sample–based biomarker research and led single-cell multi-omics initiatives to uncover mechanisms of disease and therapeutic response. Her graduate research focused on the role of regulatory T cells in autoimmune liver disease. Ruth holds a Ph.D. in Immunology from the University of California, Davis, and a B.A. in Molecular and Cell Biology from the University of California, Berkeley.

Joyce is the Senior Vice President of Finance at Ouro Medicines. Prior to this role, she was the Vice President of Finance at Human Immunology Biosciences (HI-Bio), where she was the first finance hire and led the finance function through the company’s acquisition by Biogen. Before HI-Bio, Joyce spent nearly seven years at Genentech, where she led finance for the early development portfolio, consisting of R&D assets ranging from development candidate through Phase 2. She also held key roles spanning business development finance, manufacturing finance and investor relations. Earlier in her career, Joyce worked at Burrill & Company, a biotech venture capital firm, and at Abunda Nutrition. Joyce holds a BS in Biology (Molecular) from the California Institute of Technology and an MBA from Harvard Business School.

Sarah Maddux is Vice President of Clinical Operations at Ouro Medicines, with over two decades of global experience driving clinical development from Phase 1 through Phase 4. She has led teams for biologics and small molecule programs across autoimmunity/ immunology, respiratory, women’s health, hematology, and oncology, consistently delivering operational excellence and advancing pipeline success. Prior to Ouro, Sarah held senior leadership roles at AbbVie, Karyopharm Therapeutics and Atomwise, where she spearheaded high-impact development programs and innovative strategies to optimize execution. She holds a Bachelor of Science in Food and Nutrition from Loyola University Chicago.

Charlie is Head of Portfolio Strategy at Ouro Medicines and a member of the founding team. Prior to Ouro, he was a management consultant at Bain & Company and practiced as a physician at the Royal Free London NHS Foundation Trust. Charlie is also an Investment Manager at Monograph Capital, a Board Member of RegASK and a Board Observer of Nocion Therapeutics. Charlie completed his medical training at the University of Cambridge and the University of Oxford, and holds a MPH from Harvard University as a Fulbright Sholar.